- Investing Ideas
- U.S. Pharmaceuticals & Biotech Large Cap High Growth Potential
U.S. Pharmaceuticals & Biotech Large Cap High Growth Potential
Results
16
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
16 companies
Madrigal Pharmaceuticals
Market Cap: US$11.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$518.58
7D
-0.03%
1Y
58.2%
Insmed
Market Cap: US$29.2b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$135.03
7D
-6.1%
1Y
85.9%
Ionis Pharmaceuticals
Market Cap: US$11.9b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$74.83
7D
0%
1Y
143.7%
Alnylam Pharmaceuticals
Market Cap: US$40.2b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$301.19
7D
-4.0%
1Y
18.1%
Ascendis Pharma
Market Cap: US$13.6b
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
ASND
US$220.28
7D
-2.1%
1Y
n/a
Neurocrine Biosciences
Market Cap: US$13.2b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$131.23
7D
0.8%
1Y
23.1%
BeOne Medicines
Market Cap: US$32.3b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$290.80
7D
-3.0%
1Y
13.8%
BridgeBio Pharma
Market Cap: US$13.8b
A biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
BBIO
US$70.94
7D
-1.0%
1Y
84.7%
Jazz Pharmaceuticals
Market Cap: US$12.3b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$199.92
7D
-0.02%
1Y
70.6%
Eli Lilly
Market Cap: US$782.1b
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$851.21
7D
-7.6%
1Y
-5.3%
Natera
Market Cap: US$27.6b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$194.75
7D
-3.2%
1Y
28.7%
Royalty Pharma
Market Cap: US$29.4b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$49.49
7D
-0.5%
1Y
50.8%
Viatris
Market Cap: US$17.4b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$14.97
7D
1.5%
1Y
76.7%
Elanco Animal Health
Market Cap: US$11.1b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$21.80
7D
-2.9%
1Y
130.0%
Waters
Market Cap: US$29.5b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$292.13
7D
-12.6%
1Y
-16.0%
BioMarin Pharmaceutical
Market Cap: US$10.5b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$54.21
7D
0.4%
1Y
-13.6%